EE05422B1 - Klaritromtsiini, rasv- ja hdrofiilse komponendi segu sisaldav farmatseutiline preparaat, meetod selle valmistamiseks ning kasutamine - Google Patents

Klaritromtsiini, rasv- ja hdrofiilse komponendi segu sisaldav farmatseutiline preparaat, meetod selle valmistamiseks ning kasutamine

Info

Publication number
EE05422B1
EE05422B1 EEP200100433A EEP200100433A EE05422B1 EE 05422 B1 EE05422 B1 EE 05422B1 EE P200100433 A EEP200100433 A EE P200100433A EE P200100433 A EEP200100433 A EE P200100433A EE 05422 B1 EE05422 B1 EE 05422B1
Authority
EE
Estonia
Prior art keywords
clarithromine
drophilic
fat
component
mixture
Prior art date
Application number
EEP200100433A
Other languages
English (en)
Estonian (et)
Inventor
Fercej Temeljotov Darja
Mohar Milojka
Salobir Mateja
Barbara Rebic Ljubomira
Opresnik Marko
Original Assignee
Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. filed Critical Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D.
Publication of EE200100433A publication Critical patent/EE200100433A/xx
Publication of EE05422B1 publication Critical patent/EE05422B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP200100433A 1999-02-19 2000-02-17 Klaritromtsiini, rasv- ja hdrofiilse komponendi segu sisaldav farmatseutiline preparaat, meetod selle valmistamiseks ning kasutamine EE05422B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9900039A SI20150A (sl) 1999-02-19 1999-02-19 Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
PCT/SI2000/000002 WO2000048607A1 (en) 1999-02-19 2000-02-17 Directly compressible matrix for controlled release of single daily doses of clarithromycin

Publications (2)

Publication Number Publication Date
EE200100433A EE200100433A (et) 2002-12-16
EE05422B1 true EE05422B1 (et) 2011-06-15

Family

ID=20432410

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100433A EE05422B1 (et) 1999-02-19 2000-02-17 Klaritromtsiini, rasv- ja hdrofiilse komponendi segu sisaldav farmatseutiline preparaat, meetod selle valmistamiseks ning kasutamine

Country Status (21)

Country Link
EP (1) EP1150686B1 (pl)
AT (1) ATE286736T1 (pl)
AU (1) AU776912B2 (pl)
BG (1) BG65324B1 (pl)
CY (1) CY1107454T1 (pl)
CZ (1) CZ302781B6 (pl)
DE (1) DE60017361T2 (pl)
DK (1) DK1150686T3 (pl)
EE (1) EE05422B1 (pl)
ES (1) ES2235834T3 (pl)
HR (1) HRP20010684B1 (pl)
HU (1) HUP0105481A3 (pl)
PL (1) PL196665B1 (pl)
PT (1) PT1150686E (pl)
RS (1) RS50298B (pl)
RU (1) RU2237480C2 (pl)
SI (2) SI20150A (pl)
SK (1) SK287525B6 (pl)
TR (1) TR200102396T2 (pl)
UA (1) UA74778C2 (pl)
WO (1) WO2000048607A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200000054A2 (tr) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
IN192748B (pl) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US6673369B2 (en) 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
EP1443910A1 (en) 2001-11-02 2004-08-11 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
BR0308989A (pt) * 2002-04-03 2005-01-04 Ranbaxy Lab Ltd Formulações de claritromicina com biodisponibilidade aperfeiçoada e processo de preparação das mesmas
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1534238A1 (en) * 2002-07-29 2005-06-01 ALZA Corporation Formulations and dosage forms for controlled delivery of topiramate
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005023221A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Clarithromycin formulations having improved biovailability
RU2268051C2 (ru) * 2003-12-15 2006-01-20 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая бактериостатическим действием, и способ ее изготовления
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
EP1732518A1 (en) * 2004-03-24 2006-12-20 Lupin Ltd. Clarithromycin extended release formulation
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60163823A (ja) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS63188621A (ja) * 1987-01-30 1988-08-04 Taisho Pharmaceut Co Ltd 矯味経口製剤
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
IL87219A0 (en) * 1987-08-07 1988-12-30 Abbott Lab Erythromycin formulations for oral administration
JP2553882B2 (ja) * 1987-08-08 1996-11-13 富士写真光機株式会社 走査結像光学系
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
DE69530973T2 (de) * 1994-02-16 2004-05-19 Abbott Laboratories, Abbott Park Verfahren zur herstellung feinteiliger pharmazeutischer formulierungen

Also Published As

Publication number Publication date
TR200102396T2 (tr) 2002-01-21
SK11972001A3 (sk) 2002-02-05
HRP20010684A2 (en) 2002-10-31
EE200100433A (et) 2002-12-16
PL196665B1 (pl) 2008-01-31
ATE286736T1 (de) 2005-01-15
HRP20010684B1 (hr) 2011-01-31
BG105914A (bg) 2002-05-31
CZ302781B6 (cs) 2011-11-02
AU2704900A (en) 2000-09-04
EP1150686B1 (en) 2005-01-12
PT1150686E (pt) 2005-05-31
UA74778C2 (en) 2006-02-15
SK287525B6 (sk) 2011-01-04
ES2235834T3 (es) 2005-07-16
RU2237480C2 (ru) 2004-10-10
SI20150A (sl) 2000-08-31
AU776912B2 (en) 2004-09-23
DE60017361T2 (de) 2005-12-22
CY1107454T1 (el) 2012-12-19
PL350419A1 (en) 2002-12-16
HUP0105481A2 (hu) 2002-05-29
HUP0105481A3 (en) 2003-04-28
CZ20012964A3 (cs) 2002-01-16
DK1150686T3 (da) 2005-04-04
DE60017361D1 (de) 2005-02-17
EP1150686A1 (en) 2001-11-07
RS50298B (sr) 2009-09-08
WO2000048607A1 (en) 2000-08-24
SI1150686T1 (en) 2005-06-30
BG65324B1 (bg) 2008-02-29
YU59201A (sh) 2004-07-15

Similar Documents

Publication Publication Date Title
EE200100433A (et) Klaritromütsiini, rasv- ja hüdrofiilse komponendisegu sisaldav farmatseutiline preparaat, meetod selle valmistamiseks ning kasutamine
WO2001076370A3 (en) Anthelmintic combinations
WO2002041882A3 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
WO2003002136A3 (en) Stable formulation of modified glp-1
BRPI0017013B8 (pt) composição de antibiótico azalídeo e método para sua obtenção
NZ513810A (en) Compositions and methods for improved delivery of hydrophobic therapeutic agents
EA200000964A1 (ru) Жидкие полимерные композиции для регулируемого выделения биоактивных веществ
PT1283700E (pt) Composicoes farmaceuticas de libertacao prolongada destinadas a administracao por via parental de compostos hidrofilos biologicamente activos
HRP20060251A2 (en) Substituted oxasolidinones and their use
WO2001058474A3 (en) Microencapsulation and sustained release of biologically active agent
BR0108347B1 (pt) composição de cosmético
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
MX9204135A (es) Composiciones estables para administracion parenteral y procedimiento para su preparacion.
ES2157886T3 (es) Composiciones tensioactivas y procedimientos.
CY1108145T1 (el) Σταθερες συνθεσεις για παρεντερικη χορηγηση
KR20150084839A (ko) 기제 및 피부 외용제
BR0015422B1 (pt) formulações de droga de liberação prolongada.
CA2395438A1 (en) Dry compositions containing hydrophobic amino acid
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa
MXPA05012655A (es) Isomeros puros d-(17a)-13 -etil-17-hidroxi -18, 19-dinorpregn- 4-eno-20-ino -3-ona-3e -y ??3z- oxima, asi como el proceso para la sintesis de la mezcla de isomeros y los isomeros puros.
JPS52120192A (en) Preparation of prostaglandin
WO2002049642A3 (en) Use of 5-hydroxy and 5-acyloxy-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic acids and their esters as agents useful for healing skin lesions and stimulants of angiogenesis
WO2002002089A3 (de) Anthelminthika zur verhinderung von parasitären infektionen bei mensch und tier iv
JO1664B1 (en) The compound has the effect of immobilizing gastric acid and the process of preparing it

Legal Events

Date Code Title Description
HC1A Change of owner name
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20130217